on 23 May 2024
Last Applicant/ Owned by
Emil-von-Behring Str. 76
Marburg
DE
D-35041
Serial Number
97774113 filed on 31st Jan 2023
Registration Number
N/A
Correspondent Address
Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP
Filing Basis
No Filing Basis
Disclaimer
NO DATA
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and b Read More
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
11th 000101
11th 000101
No 97774113
No Service/Collective Mark
No 034845.360
Yes
No
No
Yes
No
No
No
No
Status Date | Action Taken |
---|---|
05th Jun 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
23rd May 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
21st May 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
21st May 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
20th May 2024 | ASSIGNED TO LIE |
21st Dec 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
27th Oct 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
27th Oct 2023 | NON-FINAL ACTION E-MAILED |
27th Oct 2023 | NON-FINAL ACTION WRITTEN |
27th Oct 2023 | ASSIGNED TO EXAMINER |